Health Chat Transcripts
Researchers at the Cleveland Clinic led by Dr. Jeffrey Cohen have studied a compound called fingolimod which could ultimately be used to treat multiple sclerosis patients
View the full article
Mission Statement
As part of the Cleveland Clinic’s Neurological Institute, the Mellen Center for Multiple Sclerosis offers state-of-the-art resources to provide the most advanced specialized care, supported by an extensive program of research and education. The Mellen Center is the largest and most comprehensive program for MS care and research worldwide, managing more than 20,000 patient visits every year. Basic and clinical research conducted at the Cleveland Clinic sheds new light on MS every year.
The center’s mission statement is guided by these fundamental principles:
- To provide you and your family with compassionate, comprehensive, innovative and technologically advanced care of the highest quality.
- To conduct clinical and basic research of national and international distinction.
- To educate clinicians, academicians, investigators and allied health care providers about MS and to promote the education of our patients, their families and the general public about the disease.
Please Note: The Mellen Center does not provide Remote Medical Second Opinions.
News from the Mellen Center
Clevelandclinic.org/maps Launched to Help Patients and Visitors Find Their Way to Main Campus
A new Internet tool – clevelandclinic.org/maps – has been created to make it easier for patients and visitors to find their way to and around main campus...
read more
Investigational Oral Compound to Treat MS Effective, According to Phase III Trial
Two oral medications (pills) to treat multiple sclerosis have received recent attention, fingolimod (also known as FTY720) and cladribine. These are not pill forms of medications already-approved for MS (Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, and Tysabri) but are new medications...
read more
Chronic cerebrospinal venous insufficiency in relation to MS
Recent publications from a center in Italy have raised the idea that patients with MS may have an increased risk of narrowing of the veins draining the brain and spinal cord...
read more
Cleveland Clinic Receives $2.75 Million Grant To Study Stem Cell Treatment For MS
Jeffrey Cohen, M.D., of Cleveland Clinic’s Mellen Center, will conduct a Phase I study to determine the feasibility and safety of using mesenchymal stem cells to treat MS...read more
Medications on the Move: Ampyra
After years of research, Acorda Therapeutics, a biotechnology company, has received marketing approval from the FDA for Ampyra, an oral treatment to improve walking in patients with multiple sclerosis (MS)...read more
